ETFs Novo Nordisk A/S

NOVO B

DK0062498333

Name	Varia. Jan 1.	Weight	AuM
XACT NORDEN (UCITS ETF) - EUR	+3.28%	21.31%	1,387 M€
FIRST TRUST IPOX EUROPE EQUITY OPPORTUNITIES ETF - DISTRIBUTING - USD	+4.50%	10.45%	4 M€
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY	-0.48%	5.4%	26 M€
VANGUARD INTERNATIONAL EQUITY INDEX FUNDS - VANGUARD FTSE ALL-WORLD EX-US ETF	+2.80%	1.02%	33,076 M€
HARTFORD MULTIFACTOR DEVELOPED MARKETS (EX-US) ETF - USD	+9.26%	0.89%	1,111 M€
VANECK WORLD EQUAL WEIGHT SCREENED UCITS ETF - EUR	+3.97%	0.57%	1,212 M€

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.7%); - rare disease treatment products (6.3%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe and Canada (21.4%), the United States (56%), Latin America/Middle East/Africa (9.9%), China/Hong Kong/Taiwan (6%), Asia/Pacific (6.7%).

Employees

69,150

Sector

Pharmaceuticals

Calendar

03-26 - Annual General Meeting

More about the company

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

310.60DKK

Average target price

379.36DKK

Spread / Average Target

+22.14%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Copenhagen Other stock markets 19:20:00 13/02/2026 +03			5-day change	1st Jan Change
310.60 ^DKK	+1.32%		+5.11%	-4.50%

02-13	Hedge funds bet big against Hims & Hers Health before Wegovy showdown, Hazeltree data shows	RE
02-13	Novo Nordisk's Wegovy Tablet Reaches 38,000 New Prescriptions in the US	FW